CARB-X funds Trellis Bioscience to support the development of a monoclonal antibody designed to disrupt superbugs’ protective coating so that antibiotics can kill them

  14 January 2020

CARB-X is awarding Trellis Bioscience, of Redwood City, California, USA, up to $3.2 million in non-dilutive funding, with the possibility of $3.8 million more if certain project milestones are met, to develop an innovative monoclonal antibody designed to disrupt the protective biofilm that makes bacteria resistant to antibiotics. With the biofilm coating compromised, the bacteria are more vulnerable to being eliminated by existing antibiotics and by the body’s own immune system.  The CARB-X award will support antibody manufacturing for Phase 1.

Source: CARB-X
Author(s): Jennifer Robinson
Smart Innovations  
Back


Display your AMR technology / product:

Global AMR Technologies Database

  • Preventive – Diagnostic – Antimicrobial technologies
  • Academia – Research Institutes – Start ups – SMEs – Multinationals
  • Early research <-> near market (max 5)
  • Global reach for funding / co-development / licensing
Display your technology >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!